Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial

Overview of attention for article published in Lancet Oncology, February 2015

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 6 news outlets
blogs: 3 blogs
policy: 2 policy sources
twitter: 27 X users

patent: 87 patents
facebook: 5 Facebook pages
f1000: 1 research highlight platform
guideline: 3 clinical guideline sources

Readers on

mendeley: 882 Mendeley

So far, Altmetric has seen 6 news stories from 6 outlets.

Cost-effectiveness of Nivolumab in Patients With NSCLC in the United States

AJMC, 24 Aug 2021

Study Design: Trial- and cohort-based cost-effectiveness analyses. Methods: The analyses used partitioned survival models with…

Emerging Therapies Expand Options in Lung Cancer

OncLive, 23 Jul 2021

During the past 12 months, the treatment landscape for patients with non–small cell lung cancer has expanded dramatically with…

ASCO Reading Room | Immunotherapies Rapidly Reaching Cancer Patients in Clinical Practice

MedPage Today, 29 Jun 2018

Immune checkpoint inhibitors have rapidly changed the practice of clinical oncology, and have been adopted at a much quicker…

2015 Oncology Drugs in the Pipeline

Healio.com, 01 Jun 2015

HemOnc Today’s annual Oncology Drugs in the Pipeline chart lists agents in phase 2 or phase 3 development for a variety of…

This page shows the most recent news stories that mention this research output. Click here to find out how to access more activity, including 2 additional news stories.